Abstract
Left ventricular hypertrophy (LVH) is significantly related to adverse clinical outcomes in patients at high risk of cardiovascular events. In patients with atrial fibrillation (AF), data on LVH, that is, prevalence and determinants, are inconsistent mainly because of different definitions and heterogeneity of study populations. We determined echocardiographic-based LVH prevalence and clinical factors independently associated with its development in a prospective cohort of patients with non-valvular (NV) AF. From the "Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study" (ARAPACIS) population, 1,184 patients with NVAF (mean age 72 ± 11 years; 56% men) with complete data to define LVH were selected. ARAPACIS is a multicenter, observational, prospective, longitudinal on-going study designed to estimate prevalence of peripheral artery disease in patients with NVAF. We found a high prevalence of LVH (52%) in patients with NVAF. Compared to those without LVH, patients with AF with LVH were older and had a higher prevalence of hypertension, diabetes, and previous myocardial infarction (MI). A higher prevalence of ankle-brachial index ≤0.90 was seen in patients with LVH (22 vs 17%, p = 0.0392). Patients with LVH were at significantly higher thromboembolic risk, with CHA2DS2-VASc ≥2 seen in 93% of LVH and in 73% of patients without LVH (p
| Original language | English |
|---|---|
| Article number | 21240 |
| Pages (from-to) | 877-882 |
| Number of pages | 6 |
| Journal | The American Journal of Cardiology |
| Volume | 116 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Sep 15 2015 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Medicine(all)
Cite this
Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation. / Proietti, Marco; Marra, Alberto Maria; Tassone, Eliezer Joseph; De Vuono, Stefano; Corrao, Salvatore; Gobbi, Paolo; Perticone, Francesco; Corazza, Gino Roberto; Basili, Stefania; Lip, Gregory Y H; Violi, Francesco; Raparelli, Valeria.
In: The American Journal of Cardiology, Vol. 116, No. 6, 21240, 15.09.2015, p. 877-882.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation
AU - Proietti, Marco
AU - Marra, Alberto Maria
AU - Tassone, Eliezer Joseph
AU - De Vuono, Stefano
AU - Corrao, Salvatore
AU - Gobbi, Paolo
AU - Perticone, Francesco
AU - Corazza, Gino Roberto
AU - Basili, Stefania
AU - Lip, Gregory Y H
AU - Violi, Francesco
AU - Raparelli, Valeria
PY - 2015/9/15
Y1 - 2015/9/15
N2 - Left ventricular hypertrophy (LVH) is significantly related to adverse clinical outcomes in patients at high risk of cardiovascular events. In patients with atrial fibrillation (AF), data on LVH, that is, prevalence and determinants, are inconsistent mainly because of different definitions and heterogeneity of study populations. We determined echocardiographic-based LVH prevalence and clinical factors independently associated with its development in a prospective cohort of patients with non-valvular (NV) AF. From the "Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study" (ARAPACIS) population, 1,184 patients with NVAF (mean age 72 ± 11 years; 56% men) with complete data to define LVH were selected. ARAPACIS is a multicenter, observational, prospective, longitudinal on-going study designed to estimate prevalence of peripheral artery disease in patients with NVAF. We found a high prevalence of LVH (52%) in patients with NVAF. Compared to those without LVH, patients with AF with LVH were older and had a higher prevalence of hypertension, diabetes, and previous myocardial infarction (MI). A higher prevalence of ankle-brachial index ≤0.90 was seen in patients with LVH (22 vs 17%, p = 0.0392). Patients with LVH were at significantly higher thromboembolic risk, with CHA2DS2-VASc ≥2 seen in 93% of LVH and in 73% of patients without LVH (p
AB - Left ventricular hypertrophy (LVH) is significantly related to adverse clinical outcomes in patients at high risk of cardiovascular events. In patients with atrial fibrillation (AF), data on LVH, that is, prevalence and determinants, are inconsistent mainly because of different definitions and heterogeneity of study populations. We determined echocardiographic-based LVH prevalence and clinical factors independently associated with its development in a prospective cohort of patients with non-valvular (NV) AF. From the "Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study" (ARAPACIS) population, 1,184 patients with NVAF (mean age 72 ± 11 years; 56% men) with complete data to define LVH were selected. ARAPACIS is a multicenter, observational, prospective, longitudinal on-going study designed to estimate prevalence of peripheral artery disease in patients with NVAF. We found a high prevalence of LVH (52%) in patients with NVAF. Compared to those without LVH, patients with AF with LVH were older and had a higher prevalence of hypertension, diabetes, and previous myocardial infarction (MI). A higher prevalence of ankle-brachial index ≤0.90 was seen in patients with LVH (22 vs 17%, p = 0.0392). Patients with LVH were at significantly higher thromboembolic risk, with CHA2DS2-VASc ≥2 seen in 93% of LVH and in 73% of patients without LVH (p
UR - http://www.scopus.com/inward/record.url?scp=84940523674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940523674&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2015.05.060
DO - 10.1016/j.amjcard.2015.05.060
M3 - Article
C2 - 26183791
AN - SCOPUS:84940523674
VL - 116
SP - 877
EP - 882
JO - American Journal of Cardiology
JF - American Journal of Cardiology
SN - 0002-9149
IS - 6
M1 - 21240
ER -